非小細胞性肺がん(Non-Small Cell Lung Cancer):治療薬市場2017(世界市場規模、APIメーカー、市販薬、フェーズ3治験薬)

◆英語タイトル:Non-Small Cell Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
◆商品コード:DIIR2016103
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2017年11月
◆ページ数:約100
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

※当調査レポートでは、非小細胞性肺がん(Non-Small Cell Lung Cancer)治療薬の世界市場動向について調査・分析し、以下の構成でお届けいたします。

・非小細胞性肺がん(Non-Small Cell Lung Cancer):適応症(疾患)の概要
・市販医薬品の状況
・世界のAPI(医薬品原薬)メーカー分析
・地域別APIメーカー状況(アメリカ、ヨーロッパ、中国など)
・非小細胞性肺がん(Non-Small Cell Lung Cancer)のフェーズ3治験薬の状況
・非小細胞性肺がん(Non-Small Cell Lung Cancer)治療薬の市場規模(販売予測)
・非小細胞性肺がん(Non-Small Cell Lung Cancer)の市販医薬品分析
 (医薬品名、説明、APIメーカー、承認状況、特許など)
・非小細胞性肺がん(Non-Small Cell Lung Cancer)のフェーズ3治験薬分析
・開発中止中の非小細胞性肺がん(Non-Small Cell Lung Cancer)治療薬剤
【レポートの概要】

SUMMARY
DelveInsight’s Report, “Non-Small Cell Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Non-Small Cell Lung Cancer Report is to understand the market and pipeline status of the drugs around the Non-Small Cell Lung Cancer to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2019. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Non-Small Cell Lung Cancer. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


SCOPE:
• A snapshot of the global Market and Phase III therapeutics scenario for Non-Small Cell Lung Cancer.
• A review of the marketed products under prescription for Non-Small Cell Lung Cancer, regulatory information and marketing status.
• Coverage of global patent coverage and detailed commentaries on the US patent challenges.
• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
• Product profiles for marketed products for Non-Small Cell Lung Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
• Coverage of API Manufacturers for Non-Small Cell Lung Cancer drugs in the United States, Europe and Asian Regions with location details.
• Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Non-Small Cell Lung Cancer drugs.
• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Non-Small Cell Lung Cancer drugs.
• Coverage of Non-Small Cell Lung Cancer Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
• Key discontinued Marketed products.
• Global Sales Figure to 2019.


【レポートの目次】

1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2019
6. Marketed Drugs for Non-Small Cell Lung Cancer
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Non-Small Cell Lung Cancer
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Non-Small Cell Lung Cancer
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer

List of Tables
• Non-Small Cell Lung Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2017
• Non-Small Cell Lung Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017
• Non-Small Cell Lung Cancer Therapeutic Market, US, (Year), 2017
• Non-Small Cell Lung Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2017
• Non-Small Cell Lung Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2017
• Non-Small Cell Lung Cancer Drugs, API Manufacturers, Europe by Country, 2017
• Non-Small Cell Lung Cancer Drugs, API Manufacturers, India by State, 2017
• Non-Small Cell Lung Cancer Drugs, API Manufacturers, China by Province, 2017
• Non-Small Cell Lung Cancer Drugs, API Manufacturers by Geography 2017
• Non-Small Cell Lung Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
• Non-Small Cell Lung Cancer Therapeutic Market, Global Sales-2019 (in million USD)
• API Manufacturers for Drug, 2017
• Phase III Drugs for Non-Small Cell Lung Cancer, 2017
• Discontinued Drugs for Non-Small Cell Lung Cancer, 2017


List of Figures
• Non-Small Cell Lung Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017
• Non-Small Cell Lung Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017
• Non-Small Cell Lung Cancer Therapeutic Market, US, (Year), 2017
• Non-Small Cell Lung Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2017
• Non-Small Cell Lung Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2017
• Non-Small Cell Lung Cancer Drugs, API Manufacturers, Europe by Country, 2017
• Non-Small Cell Lung Cancer Drugs, API Manufacturers, India by State, 2017
• Non-Small Cell Lung Cancer Drugs, API Manufacturers, China by Province, 2017
• Non-Small Cell Lung Cancer Drugs, API Manufacturers by Geography 2017
• Non-Small Cell Lung Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
• Non-Small Cell Lung Cancer Therapeutic Market, Global Sales 2019 (in million USD)
• Drug, Patent/Exclusivity Expiry (Year), 2017


【レポートのキーワード】

非小細胞性肺がん(Non-Small Cell Lung Cancer)、薬剤、治療薬、市場規模、販売量、医薬品有効成分(API)メーカー、治験、上市品(市販薬)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 非小細胞性肺がん(Non-Small Cell Lung Cancer):治療薬市場2017(世界市場規模、APIメーカー、市販薬、フェーズ3治験薬)(Non-Small Cell Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆